Table 1.
Baseline characteristics
| Characteristics | Patients (n=32) |
| Age, years-median (range) | 57.5 (31-69) |
| ≥60 years | 14 (43.8) |
| Male sex | 30 (93.8) |
| Ethnicity | |
| Han ethnic group | 30 (93.8) |
| Others | 2 (6.3) |
| Smoking status | |
| Former | 0 |
| Current | 29 (90.6) |
| Never | 3 (9.4) |
| Drinking status | |
| Former | 26 (81.3) |
| Current | 2 (6.3) |
| Never | 4 (12.5) |
| ECOG performance status | |
| 0 | 16 (50.0) |
| 1 | 16 (50.0) |
| Primary tumor site | |
| Pyriform sinus | 14 (43.8) |
| Posterior hypopharyngeal wall | 9 (28.1) |
| Postcricoid | 9 (28.1) |
| T stage by AJCC 8th edition | |
| T2 | 5 (15.6) |
| T3 | 4 (12.5) |
| T4 | 23 (71.9) |
| N stage by AJCC 8th edition | |
| N1 | 2 (6.3) |
| N2 | 12 (37.5) |
| N3 | 18 (56.3) |
| TNM staging | |
| T4bN1-2 | 14 (43.8) |
| T2-4aN3 | 10 (31.3) |
| T4bN3 | 8 (25.0) |
| Differentiation | |
| Low | 13 (40.6) |
| Moderate | 16 (50.0) |
| High | 3 (9.4) |
| Lymph node necrosis | 16 (50.0) |
| Carotid invasion | 27 (84.4) |
| p16 positivity | 3 (9.4) |
| EGFR expression | |
| High (IHC3+) | 27 (84.4) |
| Low (IHC2+) | 4 (12.5) |
| Not available | 1 (3.1) |
| PD-L1 combined positive score | |
| ≥1 | 14 (43.8) |
| ≥20 | 4 (12.5) |
| Not available | 1 (3.1) |
Data are n (%) unless otherwise specified. Baseline characteristics were analyzed in 32 enrolled patients who received at least one dose of study treatment.
AJCC, American Joint Commission on Cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; PD-L1, programmed death ligand 1; TNM, tumor/node/metastasis.